Compare ELME & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | KALA |
|---|---|---|
| Founded | 1960 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.9M | 172.0M |
| IPO Year | 1994 | 2017 |
| Metric | ELME | KALA |
|---|---|---|
| Price | $2.05 | $2.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $12.67 | ★ $31.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | ★ 707.44% | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $206,360,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.98 | $0.07 |
| 52 Week High | $17.68 | $20.58 |
| Indicator | ELME | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 46.58 | 59.31 |
| Support Level | $1.99 | $0.32 |
| Resistance Level | $2.19 | $3.96 |
| Average True Range (ATR) | 0.03 | 0.37 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 70.00 | 7.27 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. It derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Elme Communities' tenants are banking, consulting, law, and financial services firms. The company operates in a single reportable segment which includes the ownership, development, redevelopment and acquisition of apartment communities.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.